Hematology
News
The costs of surviving cancer
Annual out-of-pocket spending is 60% higher for survivors, the CDC reported.
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
News
Studies cast doubt on FDA’s accelerated cancer drug pathway
An analysis suggests cancer drugs approved based on response rate often have no confirmed clinical benefit, while another finds only one-fifth of...
News
Daratumumab regimen shows benefit in transplant-ineligible myeloma
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem...
News
Genetic analysis identifies prognostic markers in CLL
A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...
Article
Call for 2019 AVAHO Abstracts
News
Family history plays a large role in bleeding disorder diagnosis in women
The survey of women with congenital bleeding disorders in Europe highlighted delays in diagnosis and burdens on activities of daily living.
Conference Coverage
Lenalidomide may reduce risk of progression from SMM to MM
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
